Imprime PGG: Phase II started

Biothera began an open-label, U.S. Phase II trial to evaluate 4 mg/kg of IV Imprime PGG given weekly in combination with Erbitux cetuximab in 56 patients. Erbitux is marketed by ImClone Systems Inc....